These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9546804)

  • 1. Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative.
    Landay AL; Bethel J; Schnittman S
    AIDS Res Hum Retroviruses; 1998 Mar; 14(5):445-51. PubMed ID: 9546804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
    AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.
    Hengge UR; Borchard C; Esser S; Schröder M; Mirmohammadsadegh A; Goos M
    AIDS; 2002 Jan; 16(2):151-60. PubMed ID: 11807298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.
    Moretti S; Famularo G; Marcellini S; Boschini A; Santini G; Trinchieri V; Lucci L; Alesse E; De Simone C
    Antioxid Redox Signal; 2002 Jun; 4(3):391-403. PubMed ID: 12215207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
    Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial evaluation of percentage of activated T-lymphocytes in peripheral blood of human immunodeficiency virus infected individuals as a prognostic marker.
    Shakoor Z
    Saudi Med J; 2003 Jun; 24(6):632-6. PubMed ID: 12847593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of CD60 helper lymphocytes detected in peripheral lymphocytes of HIV-1 infected individuals is not paralleled in lymph nodes.
    Bogner JR; Gruber R; Steckmeier B; Goebel F; Rieber EP
    Eur J Med Res; 2000 Apr; 5(4):150-6. PubMed ID: 10799349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in CD8 cell subpopulations induced by antiretroviral therapy in human immunodeficiency virus infected patients.
    Silvestri G; Munoz C; Butini L; Bagnarelli P; Montroni M
    Viral Immunol; 1997; 10(4):207-12. PubMed ID: 9473151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.
    Engchanil C; Kosalaraksa P; Lumbiganon P; Lulitanond V; Pongjunyakul P; Thuennadee R; Tungsawad S; Suwan-apichon O
    J Med Assoc Thai; 2006 Aug; 89(8):1229-36. PubMed ID: 17048434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.